Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Orders More Relenza Flu Vaccine From GSK

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare has ordered more Relenza (zanamivir) flu vaccine from British drug maker GlaxoSmithKline. For this flu season, the Ministry has prepared the vaccine for 3 million people, which is one-third of Tamiflu (oseltamivir phosphate) stockpiles. However, among the flu cases reported nationwide, 44.5 percent are infected with H1N1 type virus, which is resistant to Tamiflu. Worried about a possible shortage of Relenza, the Ministry requested additional vaccine from GSK. The drug maker has asked drug wholesalers in Japan to adjust shipping based on inventory conditions, and MHLW has cautioned medical facilities to avoid large orders of the drug. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts